Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
Philip C. Mack(UC Davis Comprehensive Cancer Center), David R. Gandara(University of California, Davis), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Rebekah A. Burich(UC Davis Comprehensive Cancer Center), Carin R. Espenschied(Guardant (United States)), Kimberly C. Banks(Guardant (United States)), Christine E. Lee(Guardant (United States)), AmirAli Talasaz(Guardant (United States)), Oliver A. Zill(Guardant (United States)), Jonathan W. Riess(University of California Davis Medical Center), Stefanie Mortimer(Guardant (United States))
Cited by 184
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k